Prevalence and Outcomes of Medium Vessel Occlusions With Discrepant Infarct Patterns

Johanna M Ospel1,2, Petra Cimflova1,3,4,5, Martha Marko1

  • 1Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Stroke
|August 8, 2020
PubMed
Abstract

Insights

Discrepant infarcts in medium vessel occlusions (MeVOs) are common and linked to worse outcomes in acute ischemic stroke patients. Identifying these patterns is crucial for predicting prognosis.

Area of Science:

  • Neurology
  • Radiology
  • Stroke Medicine

Background:

  • Medium vessel occlusions (MeVOs) typically have a better prognosis than large vessel occlusions due to less extensive brain ischemia.
  • However, some MeVO patients exhibit infarcts outside the expected vascular territory, termed discrepant infarcts.

Purpose of the Study:

  • To determine the prevalence of discrepant infarct patterns in acute ischemic stroke patients with MeVO.
  • To evaluate the clinical impact of these discrepant infarcts on patient outcomes.

Main Methods:

  • Data from two prospective cohort studies (INTERRSeCT and PRove-IT-2) were pooled for MeVO patients.
  • Discrepant infarcts were identified using baseline CTA and follow-up imaging, with two definitions applied (basal ganglia-focused and including cortical patterns).
  • Logistic regression analyzed the association between discrepant infarcts and good (mRS 0-2) or excellent (mRS 0-1) outcomes.

Main Results:

  • The study included 262 MeVO patients.
  • Prevalence of discrepant infarcts was 39.7% (definition 1) and 21.0% (definition 2).
  • Patients with discrepant infarcts had significantly lower odds of achieving good or excellent outcomes.

Conclusions:

  • Discrepant infarcts are a common finding in MeVO patients.
  • These patterns are associated with more severe neurological deficits and poorer clinical outcomes.
  • Identifying discrepant infarcts is important for accurate prognosis in acute ischemic stroke due to MeVO.